Myogen has begun patient
enrollment in Phase III clinical trials of ambrisentan for the treatment of
pulmonary arterial hypertension.
Genome Sciences has
begun dosing patients in a Phase II clinical trial of human monoclonal antibody
to B-lymphocyte stimulator, BlyS (LymphoStat-B), for the treatment of rheumatoid
Favrille has completed
enrollment for its current Phase II clinical trial (FavId-04) with the company’s
lead investigational agent, FavId. This agent is under clinical development
for the treatment of follicular B-cell lymphomas following cytoreductive
therapy with Rituxan.
Cytheris has announced
the entry of its first recombinant human Interleukin-7 protein in a Phase
I clinical study. This cytokine targets the immune reconstitution of immunocompromised
patients, including those undergoing cancer treatment, affected by AIDS,
or recovering from a bone marrow transplant.
Group has initiated a Phase I clinical study of CPG 10101 (Actilon), a novel
synthetic TLR9 agonist, targeted for patients with chronic hepatitis C
has announced that patient enrollment has begun in a Phase I trial of an inhaled
formulation of its lead product candidate, doripenem, a broad-spectrum
Epimmune has completed
patient enrollment in the Phase I/II therapeutic HIV vaccine trial
of its EP HIV-1090 vaccine candidate.
Progen Industries Limited
has begun a new Phase II clinical study of its lead anticancer compound,
Pharmacyclics has initiated
a Phase I clinical trial evaluating the safety and efficacy of its investigational
drug motexafin gadolinium (Xcytrin) in combination with temozolomide (Temodar)
for the treatment of patients with relapsed malignant gliomas.
has initiated a Phase I clinical trial of efaproxiral (RSR13) and supplemental
oxygen with concurrent chemoradiation therapy in patients with locally
advanced, unresectable (Stage IIIA/Stage IIIB) non-small cell lung cancer.
is beginning Phase I safety and immunogenicity testing for its DNA-based therapeutic
vaccine to treat hepatitis B.